Neurohormonal Hypothesis in Heart Failure

A ccording to the neurohormonal model, heart failure is a syndrome that develops because an initial heart injury activates endogenous neurohormonal systems that exert a deleterious effect to the myocardium and on the circulation. This new model regards heart failure primarily as a neurohormonal disorder with main pathophysiologic abnormality the activation of various neurohormonal systems. Arterial underfilling wether from high or low output heart failure is the predominant determinant of the neurohormonal hypothesis since it leads to activation of various compensatory competitive mechanisms in order to restore intrarterial volume and thus preserve blood flow to organs like brain and kidneys. In detail this arterial underfilling is sensed by certain mechanoreceptors on the highpressure side of the circulation like the left ventricle, the carotid sinus, the aortic arch and the renal afferent arterioles. Arterial underfilling stimulates these mechanoreceptors and afferent and efferent signals leads to activation of several compensatory – competitive mechanisms which restore arterial circulatory integrity (Figure 1). These compensatory competitive mechanisms are: 1. Activation of the sympathetic adrenergic system. 2. Activation of the renin – angiotensin – aldosterone system (RAAS). 3. Non-osmotic vasopressin release. 4. Stimulation of thirst. 5. Release of biologically active molecules like natriuretic peptides, prostaglandins, endothelins, nitric oxide and cytokines. The use of two contradictory terms to describe the above mechanisms, ie compensatory – competitive is due to that, these mechanisms when activated for a short term are truly compensatory since they appear able to sustain and modulate LV function in a setting of arterial underfilling, whereas if activated for long term like in chronic heart failure, are competitive since they adversely affect the hemodynamic condition and exert deleterious effect on the heart and on the circulation (Figure 2). Two are the main key points of the neurohormonal hypothesis: a. These mechanisms exert their deleterious effects on the heart and the circulation independently of the hemodynamic status of the patient. b. The long-term activation of these mechanisms leads to overexpression of biologically active molecules which in turn produce direct end-organ damage in the heart (LV remodeling) and the circulation (endothelium, kidneys) leading to progression of heart failure. In other words, the activation of these compensatory – competitive mechanisms accordingly to neurohormonal hypothesis is not simply the result of cardiac dysfunction but can also contribute to the development of cardiac dysfunction. In terms of the neurohormonal hypothesis, the means by which the above compensatory – competitive mechanisms accomplish their short-term beneficial effects as well as their long-term adverse effects is the overexpression of portfolios Neurohormonal Hypothesis in Heart Failure

[1]  E. Braunwald,et al.  Augmentation of the plasma nor-epinephrine response to exercise in patients with congestive heart failure. , 1962, The New England journal of medicine.

[2]  S. Satoh,et al.  Effects of renal nerve stimulation, norepinephrine and angiotensin II on renal blood flow in relation to release of PG-like substances in anesthetized dogs. , 1981, Archives internationales de pharmacodynamie et de therapie.

[3]  A. D. de Bold,et al.  A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. , 1981, Life sciences.

[4]  N. Hollenberg,et al.  Relation of the Renin‐Angiotensin-Aldosterone System to Clinical State in Congestive Heart Failure , 1981, Circulation.

[5]  H. Brunner,et al.  The Renin-Angiotensin-Aldosterone System in Congestive Heart Failure , 1983 .

[6]  J. Cohn,et al.  Increased plasma arginine vasopressin levels in patients with congestive heart failure. , 1983, Journal of the American College of Cardiology.

[7]  J. Cohn,et al.  Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. , 1984, The New England journal of medicine.

[8]  M. Packer,et al.  Prostaglandins in severe congestive heart failure. Relation to activation of the renin--angiotensin system and hyponatremia. , 1984, The New England journal of medicine.

[9]  P. Poole‐Wilson,et al.  Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. , 1987, British heart journal.

[10]  P A Poole-Wilson,et al.  Edema of cardiac origin. Studies of body water and sodium, renal function, hemodynamic indexes, and plasma hormones in untreated congestive cardiac failure. , 1989, Circulation.

[11]  G. Schreiner,et al.  Interleukin 1 and tumor necrosis factor inhibit cardiac myocyte beta-adrenergic responsiveness. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[12]  M. Pfeffer,et al.  Ventricular Remodeling After Myocardial Infarction: Experimental Observations and Clinical Implications , 1990, Circulation.

[13]  H. Itoh,et al.  Atrial natriuretic polypeptide inhibits hypertrophy of vascular smooth muscle cells. , 1990, The Journal of clinical investigation.

[14]  S. Yusuf,et al.  Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). , 1990, Circulation.

[15]  H. Fillit,et al.  Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. , 1990, The New England journal of medicine.

[16]  R. Schrier,et al.  Pathogenesis of ascites formation : mechanism of impaired aldosterone escape in cirrhosis , 1991 .

[17]  J. S. Janicki,et al.  Cardiac myocyte necrosis induced by angiotensin II. , 1991, Circulation research.

[18]  G Olivetti,et al.  Cellular basis of ventricular remodeling after myocardial infarction. , 1991, The American journal of cardiology.

[19]  P. Poole‐Wilson,et al.  Plasma CGRP-like immunoreactivity in treated and untreated congestive heart failure , 1991, The Lancet.

[20]  F. Tristani,et al.  A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. , 1991, The New England journal of medicine.

[21]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[22]  S. Yusuf,et al.  Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. , 1992, The New England journal of medicine.

[23]  M. Packer The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. , 1992, Journal of the American College of Cardiology.

[24]  M. Packer,et al.  Pathophysiology of chronic heart failure , 1992, The Lancet.

[25]  F. Pagani,et al.  Left ventricular systolic and diastolic dysfunction after infusion of tumor necrosis factor-alpha in conscious dogs. , 1992, The Journal of clinical investigation.

[26]  V. Dzau Tissue renin-angiotensin system in myocardial hypertrophy and failure. , 1993, Archives of internal medicine.

[27]  L. Vaca,et al.  Cellular basis for the negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian heart. , 1993, The Journal of clinical investigation.

[28]  M. Packer How should physicians view heart failure? The philosophical and physiological evolution of three conceptual models of the disease. , 1993, The American journal of cardiology.

[29]  M. Kinoshita,et al.  Relation between endothelin-1 spillover in the lungs and pulmonary vascular resistance in patients with chronic heart failure. , 1994, Journal of the American College of Cardiology.

[30]  D. Mann,et al.  Basic mechanisms in congestive heart failure. Recognizing the role of proinflammatory cytokines. , 1994, Chest.

[31]  M. Packer,et al.  Evolution of the neurohormonal hypothesis to explain the progression of chronic heart failure. , 1995, European heart journal.

[32]  A. Quyyumi,et al.  Cardiac sympathetic nerve function in congestive heart failure. , 1996, Circulation.

[33]  A. Luchner,et al.  Blunted cGMP response to agonists and enhanced glomerular cyclic 3',5'-nucleotide phosphodiesterase activities in experimental congestive heart failure. , 1996, Kidney international.

[34]  G. Maurer,et al.  Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. , 1996, Journal of the American College of Cardiology.

[35]  J. Cohn,et al.  The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. , 1996, The New England journal of medicine.

[36]  H. Drexler,et al.  Differential effects of kinins on cardiomyocyte hypertrophy and interstitial collagen matrix in the surviving myocardium after myocardial infarction in the rat. , 1997, Circulation.

[37]  S. Anker,et al.  Tumor necrosis factor and steroid metabolism in chronic heart failure: possible relation to muscle wasting. , 1997, Journal of the American College of Cardiology.

[38]  P. Ponikowski,et al.  Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. , 1997, Circulation.

[39]  L. Lind,et al.  Proinflammatory cytokines, measured in a mixed population on arrival in the emergency department, are related to mortality and severity of disease , 1997, Journal of internal medicine.

[40]  K. Wasserman,et al.  Nitric oxide production during exercise in chronic heart failure. , 1997, American heart journal.

[41]  E. J. Brown,et al.  The effect of digoxin on mortality and morbidity in patients with heart failure. , 1997, The New England journal of medicine.

[42]  B. Massie 15 years of heart-failure trials: what have we learned? , 1998, The Lancet.

[43]  F. Clubb,et al.  Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. , 1998, Circulation.

[44]  C. Holt,et al.  Interleukin-1 in myocardium and coronary arteries of patients with dilated cardiomyopathy. , 1998, Journal of molecular and cellular cardiology.

[45]  M. Bristow Why does the myocardium fail? Insights from basic science , 1998, The Lancet.

[46]  R. Ferrari,et al.  The neuroendocrine and sympathetic nervous system in congestive heart failure. , 1998, European heart journal.

[47]  B. Lorell,et al.  Treatment with growth hormone enhances contractile reserve and intracellular calcium transients in myocytes from rats with postinfarction heart failure. , 1999, Circulation.

[48]  I. Anand Neurohormonal modulation in chronic heart failure , 1999 .

[49]  W. Abraham,et al.  Hormones and hemodynamics in heart failure. , 1999, The New England journal of medicine.

[50]  G. Schuler,et al.  Apoptosis in skeletal myocytes of patients with chronic heart failure is associated with exercise intolerance. , 1999, Journal of the American College of Cardiology.

[51]  D. Mann,et al.  Mechanisms and models in heart failure: A combinatorial approach. , 1999, Circulation.

[52]  G. Schuler,et al.  Exercise intolerance in patients with chronic heart failure and increased expression of inducible nitric oxide synthase in the skeletal muscle. , 1999, Journal of the American College of Cardiology.

[53]  M K Davies,et al.  ABC of heart failure. Pathophysiology. , 2000, BMJ.

[54]  S. Anker,et al.  The role of inflammatory mediators in chronic heart failure: cytokines, nitric oxide, and endothelin-1. , 2000, International journal of cardiology.

[55]  E. Braunwald Congestive heart failure: a half century perspective , 2001 .

[56]  E. Braunwald The Denolin lecture. Congestive heart failure: a half century perspective. , 2001, European heart journal.

[57]  F. Boomsma,et al.  Plasma A- and B-type natriuretic peptides: physiology, methodology and clinical use. , 2001, Cardiovascular research.

[58]  S. Adamopoulos,et al.  Effects of Growth Hormone Administration on Plasma Levels of Proinflammatory Cytokines and Soluble Apoptosis Mediators Fas/FasLigand in Patients with Dilated Cardiomyopathy , 2002 .

[59]  Neurohormonal modulation in chronic heart failure , 2002 .

[60]  J. N. Sharma,et al.  Cardiovascular Properties of the Kallikrein-Kinin System , 2002, Current medical research and opinion.

[61]  Richard Kamin,et al.  Bedside B-Type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study. , 2003, Journal of the American College of Cardiology.

[62]  R. Sharma,et al.  From tissue wasting to cachexia : changes in peripheral blood flow and skeletal musculature , 2004 .